Zosuquidar
CAS: 167354-41-8
Rif. 3D-FZ104159
| 1mg | Fuori produzione | ||
| 2mg | Fuori produzione | ||
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione |
Informazioni sul prodotto
- (2R)-1-{4-[(1aR,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol trihydrochloride
- (2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol
- (αR)-4-[(1Aα,6α,10bα)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-α-[(5-quinolinyloxy)methyl]-1-piperazineethanol
- 1-Piperazineethanol, 4-[(1aα,6α,10bα)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-α-[(5-quinolinyloxy)methyl]-, (αR)-
- Lsn 335979
Zosuquidar is an ATP-binding cassette transporter (ABC) inhibitor that has been shown to inhibit the function of P-glycoprotein. Zosuquidar has also been shown to have inhibitory properties against the polymerase chain reaction (PCR), which may be due to its ability to bind and interfere with the DNA polymerase enzyme or with other cellular enzymes in the PCR pathway. In vitro studies have shown that zosuquidar inhibits HIV-1 replication in CD4+ cells, and it has been used as a component of active antiretroviral therapy. The drug is also effective against solid tumours and myelogenous leukaemia. Zosuquidar is a sesquiterpene lactone with anti-inflammatory properties, which are mediated by inhibition of phospholipase A2, cyclooxygenase, lipooxygenase, and nitric oxide synthase.
